Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: hotlinktuna who wrote (94836)	9/23/2003 3:46:58 PM
From: CusterInvestor	Read Replies (2) \| Respond to of 208838

Pharmos Corporation to Present at Friedland Capital's Biotech, Medical and Healthcare Conference Featuring Companies Covered by J. M. Dutton & Associates Tuesday September 23, 1:19 pm ET ISELIN, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Pharmos Corporation's (Nasdaq: PARS - News) Executive VP & Chief Financial Officer, Robert W. Cook, will present at 12:20 pm Eastern Time on September 24th at Friedland Capital's Biotech, Medical and Healthcare Conference, featuring companies covered by the research firm J. M. Dutton & Associates, at the Harvard Club in New York City. Mr. Cook will present Pharmos' corporate message to key members of the investment community including portfolio managers, analysts, brokers and investment bankers. The presentation will be webcast live at friedlandcapitalevents.com and will be available for replay in an archived version at the same location for 60 days. ADVERTISEMENT About Pharmos Corporation Pharmos discovers, develops, and commercializes novel therapeutics to treat a range of indications, in particular neurological and inflammation-based disorders. The Company's first neuroprotective product is dexanabinol, a tricyclic dextrocannabinoid, currently undergoing clinical testing as a treatment for traumatic brain injury and as a preventive agent against post-surgical cognitive impairment. Other dextrocannabinoid compounds and CB2 receptor agonist compounds from Pharmos' proprietary synthetic cannabinoid library are being studied in pre-clinical programs targeting a variety of other disorders. For more information on Pharmos, please visit www.pharmoscorp.com. About Friedland Capital Friedland Capital has been in business since 1979. The US based corporate finance advisory firm and its principals have assisted emerging growth companies worldwide in enhancing shareholder value and achieving their US corporate finance objectives. Friedland Capital is also the world's largest sponsor of financial community and investment events, sponsoring over 150 conferences and luncheons annually in 18 US cities and three European cities, and bringing together publicly-traded global companies with the financial community in a variety of industry sectors. Friedland Capital events provide companies a platform to showcase their management teams, company strategy and business plans. Friedland Capital has offices in New York, New Jersey, Chicago and Denver. For more information regarding Friedland Capital, please visit www.friedlandcapitalevents.com. About JM Dutton & Associates